Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2025 03:00 ET | Quelle: Ikerian AG; Fundación Ver Salud (FVS)

RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®

BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI...
16. Oktober 2024 03:00 ET | Quelle: Ikerian AG

Ikerian Announces Series B Funding First close of USD 8M (CHF 6.73M) Led by Sanoptis with Commercial Agreement to Expand RetinAI Discovery in Europe

First close Series B funding round raises USD 8M (CHF 6.73M) led by new investor, Sanoptis, with participation from existing investors the THINC Ventures arm of Topcon Healthcare, Inc, Zürcher...
24. Juni 2024 07:00 ET | Quelle: Ikerian AG

Ikerian (parent company of RetinAI U.S. Inc.) receives EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models

BERN, Switzerland and BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Ikerian AG (“Ikerian”) a leader in developing software solutions for medical image and data management and artificial intelligence...
02. Mai 2024 03:00 ET | Quelle: Ikerian AG

Ikerian AG, Parent Company of RetinAI U.S. Inc. Announces Final Close of USD 6.18M (CHF 5.65M) Series A Extension Financing

RetinAI Medical AG rebranded as Ikerian AG “Ikerian”, to spearhead development beyond ophthalmology, with wholly-owned subsidiary RetinAI U.S. Inc. “RetinAI” focused on the ophthalmology and optometry...